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could be helpful in evaluating the results of com-
pression in individual patients. This method could also
be useful for trials in which bandaging systems are
compared.
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Sir,
SjoÈ gren’s syndrome (SS) is a chronic autoimmune
rheumatic disease characterized by dryness of the eyes
and mouth resulting from lymphocytic in® ltration of
the lacrimal and salivary glands. In primary SS, these
obligatory symptoms may be alone or accompanied by
systemic manifestations (articular, renal, vascular, etc.),
but no other well-de® ned connective tissue disease can
be diagnosed on the basis of these systemic symptoms.
In secondary SS, other rheumatic diseases, commonly
rheumatoid arthritis or systemic lupus erythematodes
(SLE), are coupled with the obligatory sicca symptoms
(1, 2).
Immunopathologically , circulating autoantibodies,
autoimmune in¯ ammation, lymphocytic in® ltration,
and the consequent destruction of the affected tissues
are the main features of the syndrome. Whereas bullous
skin symptoms are commonly associated with general-
ized autoimmune diseases such as SLE (3, 4), we report
here on a patient with primary SS in whom a blistering
skin eruption developed, along with the presence of
autoantibodies against type VII collagen.
CASE REPORT
A 56-year-old woman was admitted to the Department of
Dermatology because of itchy, partly blistering skin erup-
tions in 1998. Her medical history included hypertension,
thyroidectomy, subjective xerophthalmia and xerostomia, and
since 1994 she had been followed for primary SS. At that
time, ophthalmological examination indicated signi® cantly
reduced lacrimation (Schirmer’s test: 1 mm/5 min) on both
eyes. Because of the severe eye dryness, arti® cial stopping of
the lacrimal ducts was performed. Salivary gland scintigraphy,
together with the unstimulated and stimulated saliva produc-
tion, revealed markedly decreased salivary function. The
parotid gland sonography demonstrated a gross parenchymal
inhomogeneity characteristic of primary SS (5). The abnormal
laboratory ® ndings included mild hypergammaglobulinaemia
(21.1 g/l, normal value 7.5 ± 18 g/l), IgM rheumatoid factor
positivity (73.6 U/ml; normal value 514 U/ml), anti-SSA/Ro
antibody positivity, and an elevated serum b2-microglobulin
level (13 mg/ml; normal value 52 mg/ml). Anti-dsDNA and
anti-SSB/La autoantibodies were not detected. The diagnosis
of primary SS was established in accordance with the European
Economical Community Criteria (6, 7).
In 1998, she presented with itchy, partly blistering skin
eruptions that had lasted for several weeks and showed
no tendency to heal in response to local corticosteroid and
antiseptic preparations. Because of her previously diagnosed
diseases, she was regularly taking levothyroxine, nifedipine,
chloroquine and bromhexine-hydrochloride, and she was
using arti® cial tear.
On admission, physical examination revealed numerous 1 ±
2 cm round or oval, reddish papules with or without tense
blisters and excoriated erosions on her neck and upper trunk
(Fig. 1). No exanthems or erosions were found on the mucous
membranes, but a marked dryness was noted. The patient was
otherwise in good general health. The clinical symptoms led
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Fig. 1. Tense, clear ¯ uid-® lled bullae and crust-covered erosions on
an erythematous background on the neck and trunk.
Fig. 2. (a) Histopathologic examination of the subepidermal, non-
acantholytic bulla. Note the polymorphic perivascular in® ltration
and oedema formation in the dermis (haematoxylin-eosin stain;
original magni® cation 6100). (b) Direct immuno¯ uorescence of a
perilesional biopsy specimen showing linear deposits of IgG in the
basal membrane zone. (c) Indirect immuno¯ uorescence on salt-split
normal human skin. IgG autoantibodies from the patient’s serum
labelled exclusively the dermal ¯ oor of the blisters. (Original magni® -
cation: b, c, 6160)
to a presumptive diagnosis of bullous pemphigoid (BP), and
the patient was hospitalized. Her laboratory ® ndings included
an increased erythrocyte sedimentation rate (40 mm/h),
leukopenia (2.43 109/l), neutropenia (1.67 109/l), lymphopenia
(0.46 109/l), a positive homogeneous pattern of antinuclear
antibody on Hep-2 cells, a mildly positive LE-cell phenom-
enon, high titres of anti-SSA/Ro (196 m/ml; negative value
515 m/ml, COGENT Diagnostics Ltd.) and a moderately
elevated level of anti-dsDNA antibodies (52 IU/ml; negative
value 540 IU/ml, COGENT Diagnostics Ltd.). Cryoglobu-
lins, anti-RNP and anti-Sm antibodies were not detected, and
the liver and renal function tests and serum protein electro-
phoresis ® ndings (including the complement C3 level) were in
the normal ranges.
Routine histology of the lesional skin revealed subepi-
dermal, non-acantholytic bullae with extensive oedema formation
in the papillary dermis and polymorphic perivascular in® ltra-
tion (Fig. 2a). Direct immuno¯ uorescence examination of the
perilesional skin demonstrated linear IgG and C3 binding to
the dermal-epidermal junction (Fig. 2b). Indirect immuno-
¯ uorescence testing on 1 M NaCl-separated normal human
skin revealed that the IgG from the patient’s serum labelled
exclusively the dermal ¯ oor of the blisters (Fig. 2c). Circulat-
ing autoantibodies against speci® c antigenic epitopes of the
BP autoantigens (BP230 and BP180) were not detected by
immunoblotting and an ELISA technique (8 ± 10) (data not
shown). Immunoblotting with human dermal protein extracts
as substrates indicated the presence of circulating auto-
antibodies against intact tissue type VII collagen in the patient’s
serum. The patient’s serum reacted with two dermal compo-
nents, 250 and 270 kDa, the former corresponding to the band
obtained with a monoclonal antibody against collagen VII
(SIGMA, St. Louis, MO).
Medium-dose oral prednisolone (50 mg/day) was started
with local antiseptic therapy, and a rapid improvement was
observed. The dose of prednisolone was gradually tapered off
to 25 mg every other day, and the patient remained symptom-
free for 6 months, when she died following an acute
myocardial infarction.
DISCUSSION
We describe a patient with primary SS in whom a
blistering skin disease developed. Although her subjective
xerophthalmia had been present since 1985, and xeros-
tomia since 1990, the diagnosis of SS was established
only in 1994. Besides eyedrops, the patient was treated
with chloroquine and bromhexine-hydrochloride , and
remained in a good general condition until 1998, when
her bullous skin eruption developed.
It was then necessary to exclude BP and other
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primary subepidermal bullous diseases with auto-
antibodies to hemidesmosomal or lamina lucida antigens.
The deposition of IgG on the dermal side of the basal
membrane zone, together with the presence of
circulating autoantibodies to type VII collagen,
suggested epidermolysis bullosa acquisita (EBA) and
bullous SLE. The absence of mechanical skin fragility
and formation of scars and milia exclude the
possibility of the mechanobullous (non-in¯ ammatory)
form of EBA, but do not exclude the possibility of the
generalized in¯ ammatory EBA (11).
As the LE cell phenomenon was mildly positive and
the level of the anti-dsDNA antibodies was moderately
elevated, the possibility of SLE arose. However, the
patient’s clinical symptoms and laboratory ® ndings did
not meet the SLE criteria of the American Rheumatism
Association (12). Apart from this, the case fully satis® ed
all the immunohistological requirements for bullous
SLE (3, 4, 13). 1) An acquired, widespread, non-
scarring vesiculobullous eruption; 2) subepidermal blister
formation with acute in¯ ammation in the upper dermis;
3) linear IgG and C3 depositions in the dermal-
epidermal junction zone; 4) linear IgG deposits on the
dermal side of salt-split skin, indicating circulating
autoantibodies to components of the lamina densa or
anchoring ® brils (such as type VII collagen). The
striking similarities between this case and bullous SLE
as concerns the clinical, laboratory, immuno¯ uores-
cence and immunoblotting data led us to believe that
this atypical blistering eruption was associated with
primary SS. Nevertheless, it cannot be absolutely
excluded that in our patient a primary SS was coupled
with atypical SLE, forming an overlap syndrome in
this patient (13). A long-term follow-up would have
solved this diagnostic problem, but this did not prove
possible as the patient died following an acute myo-
cardial infarction.
Most SS patients have elevated levels of antibodies
against many cellular and nuclear proteins and tissue
constituents. The existence of autoantibodies capable of
initiating or causing blister formation cannot therefore
be excluded in SS. Among others, circulating anti-type
VII collagen antibodies were detected in the patient’s
serum. Since these autoantibodie s are presumed to play
a central role in blister formation in EBA and bullous
SLE (3, 15), we hypothesize that the presence of anti-
type VII collagen autoantibodies was directly connected
with the blistering skin eruptions in the patient, and
these autoantibodies may contribute to the initiation of
bullous skin symptoms in other autoimmune disorders
as well.
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